Fusion Antibodies
FAB · AIM · Health Care · mcap £14m · 10.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 05 Oct 26 | Launch of new customer-focused website
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the launch of its new customer-focused website. |
+0.0% | |
| 22 Sep 26 | Routine | Posting of Annual Report & Notice of AGM | |
| 15 Sep 26 | Results | Final Results
The following amendment has been made to the announcement released on 14 September 2026 at 7am under RNS No. |
+16.2% |
| 14 Sep 26 | Results | Final Results
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its final results for the year ended 31 March 2026 |
−21.3% |
| 09 Sep 26 | Grant of Canadian Patent for OptiMAL
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company's patent application no. |
−2.2% | |
| 09 Sep 26 | Routine | Notice of Results | |
| 06 Aug 26 | Notice of acceptance of patent in Australia
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that IP Australia has issued a notice of acceptanc |
+2.4% | |
| 20 Jul 26 | Routine | Grant of options | |
| 01 Jul 26 | Holding | Holding(s) in Company | |
| 30 Jun 26 | Routine | Total Voting Rights | |
| 22 Jun 26 | Notice of allowance of patent in Canada
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Canadian Intellectual Property Office has |
+0.0% | |
| 15 Jun 26 | Update on grant-funded DR5 project
Project to develop a DR5 humanised therapeutic antibody to combat treatment-resistant cancers |
−2.1% | |
| 02 Jun 26 | Routine | Exercise of options and total voting rights | |
| 11 May 26 | Holding | Holding(s) in Company | |
| 11 May 26 | Grant of patent in Japan
Grant strengthens antibody discovery platform and licensing opportunities |
+7.4% | |
| 05 May 26 | Trading update | Year-end trading statement
Positioning for growth through platform development and strategic partnerships |
−10.7% |
| 30 Mar 26 | Antibody IP transfer agreement
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has entered into an agreement to transfer |
+1.2% | |
| 17 Feb 26 | Director dealing | Director/PDMR Shareholding | |
| 04 Feb 26 | Holding | Holding(s) in Company | |
| 02 Feb 26 | Holding | Holding(s) in Company | |
| 30 Jan 26 | Routine | Total Voting Rights | |
| 27 Jan 26 | Issue of Director Shares
As disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the "Board" or t |
−1.9% | |
| 27 Jan 26 | Fundraise | Placing and Subscription to raise approx £1.4m
Placing and Subscription to raise approximately £1.4 million |
−1.9% |
| 19 Dec 25 | Update on negotiations with NCI regarding OptiMAL
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the |
−8.2% | |
| 16 Dec 25 | Launch of OptiMAL platform
Launch of the OptiMAL® Human Antibody Discovery platform |
−7.1% | |
| 11 Dec 25 | Mammalian Display video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL |
+5.2% | |
| 25 Nov 25 | Holding | Holding(s) in Company | |
| 24 Nov 25 | Results | Half-year Results
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months e |
−2.1% |
| 21 Nov 25 | Routine | Notice of Results | |
| 13 Nov 25 | OptiMAL Library video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has prepared a short video of Dr Richard Buick, CSO, explain |
+2.0% | |
| 03 Nov 25 | OptiMAL® R&D Update
Validation of OptiMAL® for the isolation of specific antibodies against proteins and peptides |
+0.0% | |
| 27 Oct 25 | Holding | Holding(s) in Company | |
| 16 Oct 25 | Routine | Result of AGM | |
| 16 Oct 25 | Trading update | AGM statement and H1 trading update
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, |
+9.4% |
| 08 Oct 25 | Contract win
New multi-target Humanisation project with global pharmaceutical company |
−1.6% |
Company filings. Not investment advice.